BloodJClubFirst-line ibrutinib plus venetoclax for MCL.Blood · 17 Sept 2026 · Journal ArticleFirst-line ibrutinib plus venetoclax for MCL.Abstract ↗AI briefThe abstract is read at the publisher; the brief is JClub's.The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.Read the brief in JClub →Related in JClubCancer DiscovJClubFirst BCL-2 Inhibitor Approved for Mantle Cell Lymphoma.Cancer Discovery · 1 July 2026 · NewsSonrotoclax becomes the first BCL-2 inhibitor approved for relapsed or refractory mantle cell lymphoma, showing over 10-fold greater potency than venetoclax.In the newsOpenShareCopy linkPost on XPost on BlueskyShare on LinkedInhttps://jclub.com.au/a/42166034Open in JClub
Cancer DiscovJClubFirst BCL-2 Inhibitor Approved for Mantle Cell Lymphoma.Cancer Discovery · 1 July 2026 · NewsSonrotoclax becomes the first BCL-2 inhibitor approved for relapsed or refractory mantle cell lymphoma, showing over 10-fold greater potency than venetoclax.In the newsOpenShareCopy linkPost on XPost on BlueskyShare on LinkedInhttps://jclub.com.au/a/42166034Open in JClub